echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > East China medicine datomomycin obtained the new drug certificate of production approval

    East China medicine datomomycin obtained the new drug certificate of production approval

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    East China Pharmaceutical (000963) announced in the evening of November 26 that the company and its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd

    (hereinafter referred to as "Zhongmei Huadong") have obtained the production approval documents and new drug certificates for datomomycin and datomomycin for injection


    Daptomycin is the first product of cyclolipin antibiotic family

    Its chemical structure and mechanism of action are different from all kinds of antibiotics

    It is the only new type of antibiotic that has been used in clinic after oxazolidinone antibiotics in the past 40 years

    It is mainly used in the treatment of Staphylococcus aureus (including methicillin resistant strains), pyogenic Candida and azoospermia Complex skin and soft tissue infections (csssi) caused by Candida lactis, Neisseria gonorrhoeae, and Enterococcus faecalis (vancomycin sensitive strain), and bacteremia (SAB) caused by Staphylococcus aureus, including right infective endocarditis caused by methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) (RIE)。
    Huadong pharmaceutical said it was the first manufacturer in China to obtain the new drug certificate and production approval of datomomycin.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.